Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
Orgaran (danaparoid sodium) is an injectable anticoagulant used primarily for thromboembolism prophylaxis and treatment in patients with heparin-induced thrombocytopenia (HIT). It is a low-molecular-weight heparinoid that inhibits thrombin generation through anti-Xa and anti-IIa activity. The drug targets a niche but critical patient population requiring non-heparin anticoagulation.
Product approaching end-of-life with low competitive pressure (30/100), suggesting smaller brand teams and focus shifting toward transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Orgaran offers limited career growth opportunity given the LOE-approaching lifecycle stage and zero linked job openings. Roles are primarily maintenance-focused, managing a stable but declining product for a niche indication rather than driving innovation or market expansion. This is a consolidation or wind-down assignment for experienced professionals, not a career acceleration opportunity.
Worked on ORGARAN at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.